Immune response to an intercalated enhanced inactivated polio vaccine - Oral polio vaccine programme in Israel: Impact on the control of poliomyelitis

被引:15
|
作者
Swartz, TA [1 ]
Handsher, R
Manor, Y
Stoeckel, P
Barkay, A
Mendelson, E
Leventhal, A
机构
[1] Tel Aviv Univ, Sackler Sch Med, Dept Epidemiol & Prevent Med, IL-69978 Tel Aviv, Israel
[2] Chaim Sheba Med Ctr, Publ Hlth Labs, Cent Virol Lab, IL-52621 Tel Hashomer, Israel
[3] Assoc Aide Med Prevent, F-92430 Marnes La Coquette, France
[4] No Publ Hlth Dist, IL-17000 Nazareth, Israel
[5] Minist Hlth, Publ Hlth Serv, IL-90100 Jerusalem, Israel
关键词
EIPV/OPV combined vaccination; poliovirus vaccine efficacy; poliomyelitis control;
D O I
10.1016/S0264-410X(98)00071-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A combined enhanced inactivated polio vaccine (EIPV) and oral polio vaccine (OPV) programme was introduced in Israel in 1990, with the purpose of providing a solution to the persistent polio morbidity bz spite of a 30 year long OPV programme. The schedule comprised two noses of EIPV administered at the age of 2 and 4 months, intercalated with two doses of OPV at 4 and 6 months, followed by a reinforcing dose with the two vaccines simultaneously administered at 12 months. The 5-year evaluation of the programme included: the assessment of clinical suspicions of polio, early immune response in successive cohorts administered the new schedule, dynamics of the immune profile in a cohort followed rip to the age of 5 and monitoring of wild poliovirus excretion in sewage specimens collected in25 permanent sites throughout Israel as well as front the Palestinian Authority. No paralytic polio cases associated with a wild or vaccinal poliovirus strain were defected since the introduction of the programme. At the age of 4 months, one week after administration of the second EIPV and first OPV nose, 100% seropositivity and high geometric mean titres (GMTs) of neutralizing antibody (NA) to the three vaccinal and to the wild poliovirus type I, responsible for the 1988 polio outbreak, were observed. No change in percent of seropositivity occurred between the age of 6 and 12 months. Thirty days after the IPV and OPV reinforcing noses, GMTs to each of the foul. poliovirus strains were greater than or equal to 3037. Up to the age of 5, the seropositivity was unchanged. After a 2.5-10-fold decline in the first year following the completion of the programme, GMTs to the three vaccinal and the wild poliovirus strain levelled off at rather high values, considered protective. Between 1990 and 1995, 16 wild poliovirus type 1 strains were isolated in three separate episodes in Gaza Strip sewage and once only in one Israeli site very close to Gaza City. The rapidly established high and persistent NA titre to the vaccinal and wild poliovirus strains and the presence of immunological memory are indicative of high individual protection throughout the first 5 years of life. The only one-time introduction, without circulation, of a wild poliovirus strain in a single Israeli settlement suggests community protection. The intercalated programme offers a contribution to polio el eradication by providing a solution to the primary and secondary failure associated with OPV, as well as to the control of vaccine-associated paralytic poliomyelitis. (C) 1998 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2090 / 2095
页数:6
相关论文
共 50 条
  • [31] Viral Aetiology of Acute Flaccid Paralysis Surveillance Cases, before and after Vaccine Policy Change from Oral Polio Vaccine to Inactivated Polio Vaccine
    Subramaniam, T. S. Saraswathy
    Apandi, Mohd Apandi
    Jahis, Rohani
    Samsudin, Mohd Samsul
    Saat, Zainah
    JOURNAL OF TROPICAL MEDICINE, 2014, 2014
  • [32] LACK OF IMMUNE-RESPONSE TO ORAL POLIO VACCINE IN CHILDREN WITH CHRONIC DIARRHEA
    TOLIA, V
    ASMAR, B
    KLEIN, M
    PEDIATRIC RESEARCH, 1994, 35 (04) : A199 - A199
  • [33] Analysis of the transition from oral polio vaccine to inactivated polio vaccine for primary immunization in a hospital-based primary care practice
    Lakhiani, CN
    Vivier, PM
    Alario, AJ
    Simon, P
    Diana, BJ
    Peter, G
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (06) : 575 - 576
  • [34] First case in China of vaccine-associated poliomyelitis after sequential Inactivated and bivalent oral polio vaccination
    Peng, Xiangdong
    Hu, Xiaojiang
    Salazar, Miguel A.
    VACCINE, 2019, 37 (05) : 751 - 754
  • [35] Lower immunity to poliomyelitis viruses in Australian young adults not eligible for inactivated polio vaccine
    Hendry, Alexandra J.
    Beard, Frank H.
    Dey, Aditi
    Quinn, Helen
    Hueston, Linda
    Dwyer, Dominic E.
    McIntyre, Peter B.
    VACCINE, 2020, 38 (11) : 2572 - 2577
  • [37] ANTIBODY RESPONSE TO TYPE 1 ORAL POLIO VACCINE
    PETERSEN, I
    VONMAGNUS, H
    ACTA PATHOLOGICA ET MICROBIOLOGICA SCANDINAVICA, 1964, 62 (03): : 331 - +
  • [38] Product quality control testing for the oral polio vaccine
    Brock, B
    Kelleher, L
    Zlotnick, B
    SIMIAN VIRUS 40 (SV40): POSSIBLE HUMAN POLYOMAVIRUS, 1998, 94 : 217 - 219
  • [39] Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response
    Tzeng, Stephany Y.
    McHugh, Kevin J.
    Behrens, Adam M.
    Rose, Sviatlana
    Sugarman, James L.
    Ferber, Shiran
    Langer, Robert
    Jaklenec, Ana
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (23) : E5269 - E5278
  • [40] Introduction of Sequential Inactivated Polio Vaccine-Oral Polio Vaccine Schedule for Routine Infant Immunization in Brazil's National Immunization Program
    Domingues, Carla Magda Allan S.
    Pereira, Sirlene de Fatima
    Cunha Marreiros, Ana Carolina
    Menezes, Nair
    Flannery, Brendan
    JOURNAL OF INFECTIOUS DISEASES, 2014, 210 : S143 - S151